PAD: Doubt on harm linked to drug-coated stents
New 'robust' research failed to replicate earlier findings signalling an increased mortality risk, conference told
Data from a large real-world study do not support an earlier signal of increased mortality risk with the use of paclitaxel-coated balloons and stents in treatment of peripheral artery disease, researchers say.
Initial findings suggest that the drug-coated devices (DCDs) are not inferior to nondrug-coated devices (NDCDs) in patients receiving femoropopliteal-artery revascularisation.
The SAFE-PAD (Safety Assessment of Femoropopliteal Endovascular Treatment with Paclitaxel-Coated Devices)